GLYXAMBI: payments to doctors
Payments that named GLYXAMBI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $658K
- Providers
- 12,417
- Transactions
- 37,059
- Average per transaction
- $18
The per-transaction average — $18 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 12,417 providers the average total is $53, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $537,523 | 81.7% |
| Boehringer Ingelheim (phil.) Inc. | $51,705 | 7.9% |
| Lilly USA, LLC | $34,968 | 5.3% |
| Boehringer Ingelheim Do Brasil Quimica E Farmaceutical Ltda. | $20,094 | 3.1% |
| Boehringer Ingelheim MENA (scientific Office) Fz-llc | $8,235 | 1.3% |
| Boehringer Ingelheim India Pvt. Ltd. | $4,000 | 0.6% |
| Boehringer Ingelheim International GmbH | $1,200 | 0.2% |
| Eli Lilly Export S.A. Puerto Rico Branch | $23 | 0.0% |